1	Title: Prognostic and Diagnostic Utility of Heart Rate Variability to Predict and
2	Understand Change in Cancer and Chemotherapy Related Fatigue, Pain, and
3	Neuropathic Symptoms: A Systematic Review
4	
5	Short Title: Utility of Heart Rate Variability to Predict Cancer Related Symptoms
6	
7	Authors:
8	Jessica Bolanos ¹ , Layal Hneiny ² , Juan Gonzalez ¹ , Max O'Malley ¹ , Marlon L Wong ^{1*}
9	
10 11	¹ APReCIAT Laboratory, Department of Physical Therapy, Miller School of Medicine, University of Miami, Miami, Florida, United States of America
12 13	² Louis Calder Memorial Library, Miller School of Medicine, University of Miami, Miami, Florida, United States of America
14	
15	
16	*Corresponding author
17	E-mail: <u>mwong2@miami.edu</u>
18	
19	
20	
21	
22	

23 Abstract

24	Advances in early cancer detection and treatment have significantly improved
25	survival rates, resulting in over 18.1 million cancer survivors in the United States. Many
26	of these survivors experience chronic pain, fatigue, and neuropathic symptoms related
27	to cancer or its treatments. Emerging evidence suggests that autonomic nervous
28	system dysfunction plays a crucial role in these symptoms. Heart rate variability (HRV),
29	a measure of autonomic function, has shown potential in predicting the onset of somatic
30	symptoms in cancer patients. This systematic review aimed to assess the association of
31	HRV with pain, fatigue, and neuropathy in cancer patients and survivors.
32	A comprehensive search was conducted across multiple databases, yielding 19
33	studies that met inclusion criteria. These studies varied in cancer types, stages, and
34	HRV measurement methods. Most studies focused on breast cancer and reported a
35	predominant female population. Fatigue was the most studied symptom, followed by

36 pain. HRV measures included both time and frequency domain variables, with

37 significant variability in measurement duration and control for confounding factors.

Findings suggest that decreased HRV is associated with increased fatigue and pain, providing potential support for a bidirectional relationship between autonomic dysfunction and these symptoms. However, the heterogeneity in HRV measurement methods and the high risk of bias in many studies highlight the need for standardized HRV protocols in cancer research. Further large-scale studies with low risk of bias are necessary to validate HRV as a reliable tool for phenotyping and managing cancerrelated symptoms.

45 Introduction

Advances in early detection and treatment has significantly improved 5-year 46 47 cancer-specific survival rates (1). As a result, there is currently over 18.1 million cancer 48 survivors in the United States (1), many of whom suffer from chronic pain (2), fatigue (3), or neuropathic symptoms (i.e., paresthesia and dysesthesia) associated with cancer 49 50 or cancer treatments (4, 5). There is growing evidence that dysfunction of the 51 autonomic nervous system plays a key role in the development and maintenance of 52 these comorbid symptoms (6-8). The autonomic nervous system is an important 53 regulator of stress responses, and it exhibits functional changes in chemotherapy induced peripheral neuropathy (CIPN) and in other chronic pain conditions (8, 9). The 54 55 vagus nerve is the primary nerve of the parasympathetic system, and research indicates 56 that the vagus nerve modulates pain through 3 pathways: 1) by maintaining autonomic and hypothalamic-pituitary-adrenal axis balance thereby reducing allostatic load (10), 2) 57 58 via the cholinergic anti-inflammatory pathway in which action potentials in the vagus 59 nerve inhibit production of TNF and other inflammatory cytokines (11), and 3) by modulating the function of brain networks involving the cingulate cortex and insula 60 61 which are involved in pain processing (12). Dysfunction of these pathways may also 62 contribute to cancer related fatigue and neuropathy (8, 9, 13).

Measures of heart rate variability (HRV) are commonly used as surrogate measures of autonomic function, and emerging evidence suggests that changes in HRV may predict the onset of somatic symptoms in cancer patients. In fact, a recent study found that changes in HRV preceded the onset of CIPN symptoms in people receiving oxaliplatin for gastrointestinal cancer (8), and another study found that changes in HRV

were correlated to sensory disturbance in people with CIPN (9). Decreased HRV has also been observed in other chronic pain populations, and it has been proposed that there is a bidirectional relationship between chronic pain and autonomic dysfunction (14). Therefore, HRV is a promising measurement tool for improving the phenotyping and measurement of cancer related somatic symptoms, and it is potentially a useful treatment target.

The purpose of this study was to assess the association of HRV with comorbid symptoms (i.e., pain, fatigue, and neuropathy) in cancer patients and survivors. However, the use and interpretation of HRV lacks standardization in research. Thus, this review also describes the methods used for HRV measurement in cancer research and discusses how these methods may influence findings.

79 Materials and Methods

A systematic review was conducted following the Methodological Expectations of Cochrane Intervention Reviews Manual (15), and the results were then reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) (16). The review methods were established before developing the review, and the study protocol was registered at the International Prospective Register of Systematic Reviews under CRD42023418747.

86 Search Strategy

The study inclusion criteria consisted of 1) studies including cancer patients or survivors, and 2) longitudinal cohort studies and randomized control trials (RCTs) that 89 include at least 1 HRV measure timepoint and must include an objective measure of 90 change for at least 1 of the symptoms listed (pain, fatigue, and/or neuropathy) or 3) 91 cross-sectional studies that compare HRV between groups of cancer survivors with and without one of the symptoms of interest and allow for calculation of effect sizes. A 92 search strategy was built by the clinical research librarian (LH) from Louis Calder 93 94 Memorial Library together with the Primary Investigator (MW). The medical librarian (DG) reviewed it and gave an input using the Peer Review for Electronic Search 95 96 Strategies tool (17).

97 Firstly, the search strategy was developed in the database Ovid using both the 98 Medical Subject Headings for the concepts of Heart Rate Variability, Pain and Fatigue, 99 and cancer and chemotherapy and their alternate keywords. In addition to Ovid 100 MEDLINE(R) ALL, the following databases were searched: Cochrane Central Register 101 of Controlled Trials (CENTRAL) (Cochrane Library, Wiley), Embase (Elsevier, 102 Embase.com), Cumulative Index to Nursing and Allied Health Literature (CINAHL) Plus 103 (Ebsco), the Web of Science platform (Clarivate: Science Citation Index Expanded, 104 Social Sciences Citation Index, Arts & Humanities Citation Index, Conference 105 Proceedings Citation Index-Science, Conference Proceedings Citation Index-Social 106 Science & Humanities, Emerging Sources Citation Index), Scopus (Elsevier), 107 PsycINFO, ProQuest Databases (ABI/INFORM Collection, Academic Video Online, AFI 108 Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black 109 Studies Center, Business Market Research Collection, Coronavirus Research 110 Database, Digital National Security Archive, Dissertations & Theses @ University of 111 Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch,

112	Global Newsstream, Healthcare Administration Database, Music Periodicals Database,
113	ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical
114	Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York
115	Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest
116	Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The
117	Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with
118	Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech
119	Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide
120	Political Science Abstracts) limited to Dissertations & Theses, and APA PsycInfo
121	(Ebsco).
	(Ebsco). The Medline search strategy was adapted for the other databases each
121	
121 122	The Medline search strategy was adapted for the other databases each
121 122 123	The Medline search strategy was adapted for the other databases each according to its syntax taking into consideration the use of different controlled
121 122 123 124	The Medline search strategy was adapted for the other databases each according to its syntax taking into consideration the use of different controlled vocabulary such as: EMTREE terms for Embase, Medical Subject Headings for
121 122 123 124 125	The Medline search strategy was adapted for the other databases each according to its syntax taking into consideration the use of different controlled vocabulary such as: EMTREE terms for Embase, Medical Subject Headings for Cochrane Library, and CINAHL Subject Headings for CINAHL plus, in addition to

129 Study selection, data extraction, and data management

The results that were yielded from the databases were exported into Covidence
Web-based software (18) directly or into EndNote 20 (19) then imported to Covidence.
In Covidence, the duplicates of overlapping results were removed, then the remaining
results were first screened for title-abstract, then screened for full-text (18). Each step

134 was conducted by independently by two reviewers (JB and JG), and conflicts were
135 resolved by consensus with the primary investigator (MW).

An Excel spreadsheet was developed and piloted for data extraction. Then, two independent reviewers (JB and MO) extracted data from the full-text manuscripts. Missing data was requested from the study authors via email. Seven authors were contacted in November 2024 via email requesting clarification of measures or raw data sets for symptom of interest and heart rate variability measures. Two authors responded with clarifications, two contacts were listed as undeliverable, and three authors did not respond.

143 **Risk of bias assessment and synthesis of findings**

consensus was achieved for Cochrane GRADE classification.

Our intention was to include all longitudinal studies with repeated measures of 144 145 HRV and symptoms, which would likely encompass a variety of study designs. Thus, 146 the Mixed Methods Appraisal Tool (MMAT) was chosen for risk of bias assessment due 147 to its applicability to a wide range of study types (20). Each study was assessed by two 148 independent reviewers (JG and MO) for risk of bias, and disagreements between reviewers were resolved by deliberation until a consensus is reached (Appendix 2). 149 150 The body of evidence was assessed based on the Cochrane GRADE 151 classification (high, moderate, low and very low) (21), and an Excel spreadsheet was 152 used to record the data. Four investigators (JB, JG, MO, and MW) deliberated until

154

153

155

156 **Results**

157 Study Characteristics

158	A total of 6677 titles and abstracts were screened by two reviewers. Fifty-nine full
159	text articles were assessed with 19 articles ultimately selected for inclusion (Figure 1).
160	Publication dates ranged from 2009-2023, and the studies covered a wide range of
161	cancer types (Table 1). Nine of the 19 studies focused solely on people with breast
162	cancer (22-30). Of the 19 studies, nine (26, 28, 30-36) did not report staging
163	information, however most that reported staging ranged from stage 0 to terminal with
164	most participants in stage I.
165	
166	
167	
168	
169	
170	
171	
172	
173	
174	
175	
176	
177	
178	

Table 1. Study Characteristics

First author (year)	Country	Aim of study	Design	Participants recruited	Heart rate variability measurement details	Key relevant findings		
Lee (2018)	Taiwan	To assess the effects of 12 weeks of Qigong exercise or stress management training on fatigue, fear of recurrence, quality of life, and heart rate variability in people who completed cancer treatment at least 1 month prior.	Randomiz ed control trial	99 cancer survivors	5-minute recording seated or lying prone; PPG device; time domain as primary	After 12 weeks of both Qigong and stress management training, fatigue was reduced and increases in SDNN, TP and HF were observed.		
Burch (2020)	USA	To assess if heart rate variability biofeedback treatment among cancer survivors can increase HRV coherence and reduce symptoms of pain, stress, fatigue, depression, distress, PTSD, and insomnia relative to control patients in 6 weeks.	Pilot randomize d control trial	38 cancer survivors	15-minute recording, no positioning information mentioned; ECG device; HRV coherence ratio reported as primary	Relative to controls, the intervention group experienced trends toward improvements in stress, distress, fatigue, PTSD, and depression. HRV coherence ratio increased following biofeedback training in the intervention group while no change or decrease in coherence ratio occurred with control group.		
Tsai (2021)	Taiwan	To assess what factors may influence the outcome of cancer related fatigue among female breast cancer patients undergoing chemotherapy	Cohort study	109 patients undergoing cancer treatment	15-minute recording, no positioning information given; ECG device; frequency domain as primary	Anxiety, depression, and symptom distress contributed to cancer related fatigue with symptom distress, anxiety and sleep deprivation consistently high amongst those receiving chemotherapy. No predictive		

						relationship was found between LF/HF ratio and fatigue levels.
Cheng (2019)	Taiwan	To assess if 12 weeks of mindfulness or Qigong training change outcomes for fatigue and HRV in cancer survivors	Randomiz ed control trial	66 cancer survivors	5-minute recording; no positioning information given; PPG device; time domain as primary	Reduced cancer-related fatigue was present in both the mindfulness group and the Qigong group. SDNN and TP values also increased from baseline.
Riesenberg (2009)	Germany	To assess if intensive supervised aerobic exercise is efficacious in improving HRV, quality of life, and functional status for patients with lung cancer over a 28-day period in inpatient rehab?	Cohort study	45 patients undergoing cancer treatment	12-minute recording laying down; PPG device; time domain as primary	Exercise capacity and functional status (quality of life, fatigue) improved during rehabilitation. RMSSD increased post intervention.
Chuang (2010)	Taiwan	To assess if music therapy is effective in lowering anxiety, improving mood, and improving HRV when applied for a 2-hour session one time intervention in cancer survivors	Quasi- experimen tal	23 cancer survivors	5-minute recording, no positioning information given; ECG device; frequency domain as primary	Fatigue levels were lower after music therapy. Increase in HF power and decrease in LF/HF ratio and LF power were observed post intervention.
Fernandez- Lao (2011)	Spain	To investigate the immediate effects of myofascial release on HRV and mood state and to assess the attitude towards massage in breast cancer survivors suffering cancer- related fatigue	Crossover randomize d control trial	20 cancer survivors	5min ECG, no positioning information given; ECG device; time domain as primary	Massage leads to an immediate increase in SDNN, RMSSD and HF and an improvement in mood. The impact of massage on cancer-related fatigue is modulated by the attitude of the patient towards massage, however no interaction was

						reported between belief and SDNN, RMSSD or HF values.
Chen (2019)	Taiwan	To assess the effect of a single music therapy intervention on multiple mood categories and HRV for women actively being treated for breast cancer.	Randomiz ed control trial	100 patients undergoing cancer treatment	5-minute recording, no positioning information given; ECG device; frequency domain as primary	Women who completed single session music intervention reduced symptoms post intervention compared to control group. Higher LF/HF ratio reported at baseline, but no post intervention data was given.
Aoki (2023)	Japan	To assess if HRV would be useful in evaluating fatigue and quality of life of women with breast cancer undergoing radiotherapy.	Cohort study	75 patients undergoing cancer treatment	2-minute recording, sitting; PPG device; frequency domain as primary	Cognitive and physical fatigue were highest at baseline and decreased by midpoint of treatment. Similarly, a decrease in LF/HF ratio was seen by midpoint of treatment.
Masel (2016)	Austria	To assess if HRV a valid representation for subjective pain for patients in palliative care with cancer break through pain.	Pilot study	10 patients undergoing cancer treatment	24-hour recording, no positioning data given; ECG device; frequency domain as primary	Pain reduction was seen post opioid administration. Log LF/HF ratio decreased in patients with >2 point reduction on the NRS.
Lee (2022)	Taiwan	To assess if there is a difference in HRV measures and quality of life measures when given either Qigong, mindfulness intervention or no intervention in cancer survivors at least 1 month out of treatment.	Quasi- experimen tal	125 cancer survivors	5-minute recording, sitting; PPG device; time domain as primary	Both Qigong and mindfulness interventions had short-term effects in improving overall physical and mental health, and quality of life. Increase in SDNN and total power were noted in the short term, but decreased LF was reported in the long term.

Uchida (2017)	Japan	To assess if HRV is predictive of PACU emergent pain within a 12h hour window in post operative breast cancer surgery patients.	Retrospec tive study	20 patients undergoing cancer treatment	No positioning or recording time information given; PPG device; frequency domain as primary	There was no significant difference in pain intensity between the two groups immediately after admission to PACU. Patients in the intervention group required no analgesic agents for at least 12 hours after surgery. Increased HF and decreased LF/HF ratio values were associated with adequate pain intervention.
Fagundes (2011)	USA	To assess if fatigue level is related to HRV or epinepherine at baseline and during/after a social stressor in breast cancer survivors.	Cohort study	109 cancer survivors	Continuous recording, sitting; PPG device; time domain as primary	Higher fatigue was associated with decreased RMSSD values pre and post stressor.
Niederer (2013)	Germany	To assess if exercise over a 16- week period improves HRV measures and cancer related fatigue in both cancer survivors and patients undergoing cancer treatment.	Quasi- experimen tal	45 cancer survivors and those undergoing treatment	5-minute recordings, supine; PPG device; frequency domain as primary	Exercise programing improves quality of life and increases total power values. An increase in HF and decrease in LF was also observed post intervention.
Yesil (2018)	Turkey	To assess whether neuropathic pain is associated with changes in cardiac sympathovagal activity in patients with breast cancer.	Cohort study	70 patients undergoing cancer treatment	24-hour recording, no positioning information given; ECG device; time domain as primary	SDNN was lower and LF/HF ratio was higher in patients with neuropathic pain than in those without.
Fournié (2021)	France	To evaluate the feasibility of a 12-week program combining heart rate variability biofeedback and physical	Cohort study	20 patients undergoing cancer treatment	5-minute recording, seated with knees at 90°, feet flat on the floor, hands on	No changes in fatigue outcome measures noted despite a trend towards decreasing general/physical fatigue. SDNN and RMSSD did not change

		exercise in hematologic patients.			thighs, palms facing upward, and eyes closed; PPG device; time domain as primary	over time, but increased LF and HRV coherence ratio were noted.
Murofushi (2023)	Japan	To assess if HRV can provide an objective measure for bone metastasis pain during a period of radiotherapy.	Pilot study	11 patients undergoing cancer treatment	24-hour recording, no positioning information given; PPG device; frequency domain as primary	For all samples, the NRS score showed no significant relationship with mean LF/HF ratio and HF. In patients with an NRS ≥4, the NRS score was significantly associated with LF/HF ratio but not HF.
Guimond (2018)	Canada	To assess if measures of emotional regulation are associated with measures of psychological symptoms in patients with breast cancer receiving radiotherapy.	Cross- sectional	81 patients undergoing cancer treatment	5-minute recording, no positioning information given; PPG device; time domain as primary	Low emotional regulation was marginally associated with increased depression and fatigue between timepoints. HF was not associated with symptom change.
Uchida (2017)	Japan	To assess if low dose Remifentanil effects post operative pain and HRV in breast cancer surgery patients.	Retrospec tive study	20 patients undergoing cancer treatment	No positioning or recording time information given; PPG device; frequency domain as primary	After Remifentanil administration, the value of the NRS decreased. There were no significant differences in HF and LF/HF ratio was found between groups.

180

181 *PPG= photoplethysmogram; SDNN= standard deviation of the normal-to-normal interval; TP= total power; HF= high*

182 frequency power; PTSD= post-traumatic stress syndrome; HRV= heart rate variability; ECG=electrocardiogram; LF/HF

183 ratio= low frequency/high frequency ratio; RMSSD = square root of mean squared differences of successive normal-to-

184 normal intervals; NRS= numeric rating scale; LF= low frequency; PACU= post anesthesia care unit

185	A majority of the participants across studies were middle aged (ranging from 48-
186	65 years). All but 3 of the studies (34-36) reported a predominant female population,
187	with 10 having an all-female sample (22-31). One study did not provide gender
188	information (37). Studies took place in Taiwan (N= 6)(22, 24, 31, 33, 38, 39), Japan (N =
189	4)(25, 26, 30, 36), United States of America (USA) (N = 2)(27, 40), Germany (N = 2)(34,
190	37), Canada (N = 1)(29), France (N = 1)(35), Turkey (N = 1)(28), Spain (N = 1)(23), and
191	Austria (N = 1)(32). Only 2 studies provided detailed data on race or ethnicity, and these
192	studies took place in the USA (27, 40).
193	Fatigue was the most common symptom discussed (N = 14)(22-25, 27, 29, 31,

33-35, 37-39), followed by pain (N = 5)(26, 30, 32, 36). Although 1 study assessed
neuropathic pain,(28) no studies were found on non-painful neuropathic symptoms, and
only 1 study assessed multiple symptoms (pain and fatigue) (40). Four of the included
studies were focused on the psychological effects of cancer (mood, anxiety, depression)
as a primary measure, with fatigue as a secondary measure of interest (22, 23, 31, 39).

199 Heart rate variability measures

200 All 19 studies utilized electrocardiogram (ECG) (N=6) or photoplethysmography 201 (PPG) (N=13) equipment in the form of wrist watches, handheld or chest strap tools for 202 HRV measurement. Ten of 19 studies conducted HRV measurements for 5 minutes or 203 less.(23-25, 29, 31, 33-35, 38, 39) 3 of 19 reported between 12 and 15-minute 204 recording times.(22, 37, 40) Furthermore, 4 of 19 reported continuous measurement for 205 a maximum of 24 hours.(27, 28, 32, 36) Two studies did not report on the duration of 206 the recording. (26, 30) Studies varied in participant positioning during HRV recording 207 and in level of control for confounding factors (i.e. caffeine, physical activity), with 7 of

19 studies failing to include this information in the manuscript (22, 26, 30, 32, 33, 36,39).

210 Heart rate variability and fatigue

211 Fatigue was a primary outcome for 9 studies (24, 25, 27, 29, 33-35, 37, 38).

212 Participants included cancer stages from stage I-IV, and sample sizes ranged from 17-

213 125. Measures of fatigue were heterogeneous amongst the studies, and included the

cancer fatigue scale (N= 3)(25, 33, 38), multidimensional fatigue inventory (MFI-20)

215 (N=2)(35, 37), multidimensional fatigue symptom inventory (MFSI-SF) (N= 2)(24, 27),

fatigue symptom inventory (N=1)(29) and the EORTC Core Quality of Life questionnaire

217 (EORTC-QLQ C30) (N=1)(34).

218 Five of the 9 studies reported time domain measures. Standard deviation of normal-to-normal RR intervals (SDNN) was utilized for three studies (33, 35, 38). Root 219 220 mean square of successive differences (RMSSD) was reported as a primary time 221 domain variable in 2 studies (27, 37). Of these 5 studies, only one did not report 222 secondary frequency domain variables (LF, HF, LF/HF ratio) (37). Furthermore, four of 223 9 studies only reported frequency domain variables (24, 25, 29, 34). 224 All 9 studies reported longitudinal HRV measures at distinct time points (pre 225 intervention, post intervention, follow up). Time periods between baseline and follow up 226 measures were variable, with final follow up outcome assessment ranging between 12-227 28 weeks after initial intervention. HRV devices were worn for 5-15 minutes throughout 228 the data collection process for all 9 studies, and 8 of the fatigue related studies reported

229 controlling for confounding factors of HRV including quiet sitting, decreasing caffeine

(24, 25, 27, 29, 34, 37, 38), and specific instructions like "relax and breathe
normally"(35).

232 Across 4 of the studies (27, 33, 37, 38), a decrease in fatigue scores was 233 associated with increased time domain HRV measures (SDNN, RMSSD). Only one 234 study found no change in time domain measures amongst groups (35). The 235 relationships between fatigue scores and frequency domain measures (LF/HF ratio, HF, 236 LF, TP) were mixed with two studies reporting no change in the trials (29, 35), one study 237 reporting decreased LF/HF ratio and fatigue at midpoint of treatment (25), and 3 studies 238 reporting increased total power with decreased fatigue (33, 34, 38). 239 Studies using heart rate variability with fatigue as secondary measures 240 Four studies included fatigue measures as a secondary focus, with a primary 241 focus on emotional stressors like anxiety, depression or fear of cancer recurrence (22, 23, 31, 39). Like the studies with fatigue as a primary outcome, sample sizes varied 242 243 from 20-100 participants (23, 31, 39). All 4 studies utilized ECG as a primary source of 244 HRV measurement, with recordings lasting 5-15 minutes, with 2 reporting time domain 245 variables as primary HRV outcomes (SDNN, RMSSD)(23, 39), and all four studies 246 reported frequency domain measures (LF/HF ratio, TP, HF, LF). Three of the studies 247 found that an improvement in HRV variables (increased SDNN, RMSSD, HF and 248 decreased LF/HF ratio) occurred with decreased fatigue (23, 31, 39). Only one study 249 found no predictive relationship between HRV and cancer related fatigue, and though 250 this study had the largest sample size, it was also the only study involving participants

currently undergoing cancer treatment (22).

Across these 13 studies, a decrease in fatigue scores typically occurred with an increase in time domain HRV measures, with only 1 of 7 studies that reported on time domain measures not finding this relationship. There was less consistency across fatigue related studies that used frequency domain HRV measures, although most also found a relationship. The GRADE for the evidence on HRV as a physiological marker for fatigue is **low** due to risk of bias (incomplete outcome data in 4 studies and lack of accounting for confounders in 2 studies).

259 Heart rate variability and pain

260 Of the 4 studies with pain as the primary symptom under investigation, 261 participants ranged in cancer stage of treatment from post operative to palliative care. 262 and all of the studies had small sample sizes ($n \le 20$). All 4 studies utilized the 0-10 numeric rating scale (NRS) for pain intensity, and none reported any additional pain 263 variables. Additionally, all 4 studies utilized frequency domain HRV measures including 264 265 high frequency (HF), low frequency (LF), total power (TP), and LF/HF ratio; and only 266 one study reported a time domain variable (pNN50). Only 2 of the studies reported 267 recording time frame (24 hours for both) (32, 36). HRV measurement with a PPG based 268 monitoring system was closely tied to time periods of medication administration for pain 269 management in 3 of 4 studies (26, 30, 32). Importantly, none of the four studies reported 270 controlling for confounding factors pertaining to HRV measurement (e.g., time of day, 271 phase of menstrual cycle, dietary and exercise considerations).

Three studies reported on acute pain changes (i.e., post operative and breakthrough pain)(26, 30, 32) and one on chronic pain associated with bony metastasis (36). Those studies on acute pain reported significant differences in

frequency domain variables, mainly LF/HF ratio, with improving NRS scores (26, 30,
32). Two studies reported on the role of pain free post operative period in regulating
HRV (LF/HF ratio and HF) (26, 30). With breakthrough pain specifically, an NRS
reduction of greater than 2 points equated to a decrease in LF/HF ratio and improving
function (32). With radiotherapy, higher NRS scores of greater than or equal to 4 were
associated with LF/HF ratio changes with no significant association found with NRS
scores below 4 (36).

Collectively, these studies suggest that moderate changes in pain intensity (NRS change of 2-4) may be associated with changes in HRV. However, the GRADE for this evidence is **very low** due to high risk of bias (incomplete reporting of data and lack of accounting for confounders) and imprecision (small sample sizes).

Heart rate variability and neuropathy

287 Only one study mentioned neuropathy as a symptom of interest in conjunction 288 with pain measures (28). Categorized as neuropathic pain, the study focused on breast 289 cancer patients, and no cancer stage information was given. Unlike the other studies on 290 pain, this study utilized the Leeds Assessment of Neuropathic Symptoms and Signs 291 (LANSS) scale to differentiate between neuropathic and nociceptive pain descriptors, 292 not intensity (28). ECG was utilized to measure HRV, with SDNN being the HRV 293 variable of interest. Other time domain variables (SD of the mean of the RR intervals (SDAAN), SD of the NN interval (SDDN index) and frequency domain variables (total 294 295 power (TP), LF/HF ratio) were also collected. Time domain variable values were found 296 to be lower and frequency domain variable values were found to be higher in those with 297 neuropathic pain (28). The GRADE for the evidence on HRV as a physiological marker

for neuropathy is very low due to high risk of bias (lack of accounting for confounders)
and imprecision (only 1 study).

300 **Discussion**

301 HRV is a complex measure involving the fluctuation in the time intervals between 302 heartbeats. These changes can influence regulatory outputs like blood pressure, heart 303 and vascular tone, which influences adaptation to both physical and psychological 304 stressors (41). This study aimed to assess the relationship of HRV to comorbid 305 symptoms (i.e., pain, fatigue, and neuropathy) in cancer patients and survivors. 306 Nineteen studies were identified that utilized HRV and assessed pain or fatigue. 307 However, they varied in their purpose and application of HRV with some using HRV to 308 determine the impact of symptoms on autonomic function and others using HRV as a 309 measure of systemic response to a targeted intervention.

310 HRV confounders

HRV measurements can be influenced by a variety of variables, including age, sex, and breathing rate (41). Numerous lifestyle factors including stress level, smoking, fitness level, caffeine intake and pharmacology, can also have an influence on HRV metrics (42). Thus, control and identification of these confounding factors is of upmost importance to decrease error in HRV interpretation. In our sample of studies, 7 of 19 included a description of controlling for potential confounders of HRV.

Additionally, sampling time can have an influence on accuracy of HRV metrics. The "gold standard" for clinical assessment is a 24 hour recording, as these recordings are shown to have greater predictive power (41). Short term measurements, defined as
5 minute measurements, or ultra short term measurements (<5 minutes) have been
found to correlate poorly with the 24-hour indices (41). Of the 19 articles reviewed, 10
reported short term or ultra short-term measurements, and only 4 utilized 24-hour
measurements. This may be a contributing factor to the heterogeneity in findings.

324 Further contributing to the heterogeneity, HRV can be divided into time, 325 frequency, and spectral domain measures. Notably, only time and frequency domain 326 measures were reported, as none of the 19 studies assessed spectral domain 327 measures. Time domain HRV indices (i.e. SDNN, RMSSD, pNN50, HRmax-HRmin) 328 quantify the amount of variability observed during a recording time frame (<1 minute to 329 >24 hours) (41). The SDNN has been referred to as the "gold standard" HRV variable 330 for medical stratification of cardiovascular risk when recorded over a 24-hour period (41, 331 43). In contrast, frequency domain HRV indices estimate the relative or absolute power 332 over four frequency bands ultra-low frequency (ULF), very-low frequency (VLF), low-333 frequency (LF) and high-frequency (HF) (41). The ratio of LF to HF (LF/HF ratio) was 334 originally interpreted as an estimate of sympathetic to parasympathetic balance, with 335 low LF/HF ratio symbolizing parasympathetic dominance and high LF/HF ratio 336 translating to sympathetic dominance (41). This interpretation contributes to the 337 popularity of frequency domain variables being reported over time domain. However, 338 the accuracy of this interpretation has been called into question due to the variable 339 nature of sympathetic nervous system control. Moreover, LF/HF ratio, particularly short 340 term measurements of LF/HF ratio, have been found to vary widely based on testing 341 conditions (41). Kuss et al. (44) found that frequency domain variables showed up to a

10 fold increase in variation when compared to SDNN. Of the 19 studies examined, only
9 reported a time domain measure (SDNN or RMSSD), and 17 studies reported
frequency domain measures, most commonly LF/HF ratio. The higher utilization of
frequency domain variables over time domain variables goes against existing
recommendations for HRV research, and it highlights the need for consensus guidelines
on HRV research in cancer populations.

348 Differences in Outcome Measures

349 The specific outcome measure chosen may also influence the observed relationships between HRV and pain or fatigue. The four studies on pain were noted to 350 351 all utilize the same outcome measure (NRS), focusing on pain intensity with 352 pharmacological interventions. However, pain is known to be multidimensional (45), and 353 the pain NRS is a unidimensional measure. It is possible that changes in HRV are 354 associated with aspects of pain other than intensity (e.g., pain interference on mood or sleep). In contrast, the studies that focused on fatigue utilized multidimensional 355 measures of fatigue. Specifically, the Cancer Fatigue Scale (CFS), Fatigue Symptom 356 357 Inventory (FSI) and Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-358 SF) were all validated utilizing patients with a history of cancer and all measure 359 physical, cognitive and emotional fatigue (46-48). However, outcome scores for these fatigue scales were usually reported as a total score change, with only one study 360 361 reporting subscale changes (35). It is plausible that HRV is more closely associated with 362 one aspect of fatigue than another (e.g., physical fatigue may be strongly correlated to 363 HRV but emotional fatigue is not). Given the multidimensional nature of pain and

fatigue, future studies on HRV should assess and report on multiple dimensions for thesymptoms of interest.

366 Limitations

367 Only articles in English were included, which is an important limitation of the 368 review process used in this study. Additionally, our search yielded only one study on 369 HRV and neuropathy, and this study focused on neuropathic pain. The lack of 370 longitudinal studies on HRV and neuropathy may be influenced by the lack of 371 consensus regarding the diagnostic criteria for chemotherapy induced peripheral 372 neuropathy (CIPN)(8). Another potential reason for this may be that CIPN is only found 373 with neurotoxic chemotherapies such as paclitaxel, cisplatin, and oxaliplatin which may 374 not have been prescribed in a large portion of the included abstracts for review (49). 375 Due to the heterogeneity of the HRV measurements and the relatively high risk of bias 376 across studies, we did not conduct a meta-analysis as planned. Additionally, only 2 of 377 19 studies reported on race/ethnicity in their given populations, and 10 of 19 studies 378 took place in Asia (Taiwan, Japan), which may limit the generalizability of these findings.

379 **Conclusion**

HRV is growing in use as a physiological outcome measure, and the findings of this study suggest that it may be a useful tool to determine physiological load associated with fatigue and pain in cancer patients and survivors. Fatigue and pain are common comorbidities associated with antineoplastic treatment and while their physiological impact can be seen with HRV changes, the lack of consensus with HRV

385	measurement	can	make	its	interp	pretation	difficult.	Large	studies	with	low	risk	of	bias	are	;
-----	-------------	-----	------	-----	--------	-----------	------------	-------	---------	------	-----	------	----	------	-----	---

needed as the field continues to work toward better standardization of HRV protocols.

387 Acknowledgements

- 388 For peer reviewing the Medline (OVID) database search strategy, the authors
- 389 would like to acknowledge the Research Services and Liaison Librarian David S.
- 390 Gerstle, Ph.D., MS-ILS from the University of Toronto Mississauga. The authors would
- 391 also like to acknowledge John Reynolds and Thilani Samarakoon for their input on
- 392 methodology.

393 **References**

Tonorezos E, Devasia T, Mariotto AB, Mollica MA, Gallicchio L, Green P, et al.
 Prevalence of cancer survivors in the United States. J Natl Cancer Inst. 2024;116(11):1784 90.

Arthur J, Tanco K, Park M, Haider A, Maligi C, Dalal S, et al. Personalized Pain Goal as
 an Outcome Measure in Routine Cancer Pain Assessment. J Pain Symptom Manage.
 2018;56(1):80-7.

- 400 3. Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancer-related fatigue: A critical
 401 appraisal. Eur J Cancer. 2006;42(7):846-63.
- 402 4. Kerckhove N, Collin A, Conde S, Chaleteix C, Pezet D, Balayssac D. Long-Term
 403 Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced
- 404 Peripheral Neuropathies: A Comprehensive Literature Review. Front Pharmacol. 2017;8:86.
- Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence,
 prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic
 review and meta-analysis. Pain. 2014;155(12):2461-70.
- 408 6. Stone CA, Kenny RA, Nolan B, Lawlor PG. Autonomic dysfunction in patients with
 409 advanced cancer; prevalence, clinical correlates and challenges in assessment. BMC
 410 Palliat Care. 2012;11:3.
- 7. Noor B, Akhavan S, Leuchter M, Yang EH, Ajijola OA. Quantitative assessment of
 cardiovascular autonomic impairment in cancer survivors: a single center case series.
- 413 Cardiooncology. 2020;6:11.
- 414 8. Jang A, Seol YM. Heart Rate Variability as a Non-invasive Objective Parameter for
 415 Predicting the Occurrence of Chemotherapy-induced Peripheral Neuropathy in Patients
 416 With Gastrointestinal Cancer. Anticancer Res. 2021;41(5):2637-45.

417 9. Marstrand SD, Buch-Larsen K, Andersson M, Jensen LT, Schwarz P. Vibration

418 Perception Threshold and Heart Rate Variability as methods to assess chemotherapy-

induced neuropathy in women with breast cancer - a pilot study. Cancer Treat ResCommun. 2021;28:100426.

Li S, Wang Y, Gao G, Guo X, Zhang Y, Zhang Z, et al. Transcutaneous Auricular Vagus
Nerve Stimulation at 20 Hz Improves Depression-Like Behaviors and Down-Regulates the
Hyperactivity of HPA Axis in Chronic Unpredictable Mild Stress Model Rats. Front Neurosci.
2020;14:680.

425 11. Chavan SS, Pavlov VA, Tracey KJ. Mechanisms and Therapeutic Relevance of Neuro-426 immune Communication. Immunity. 2017;46(6):927-42.

427 12. Mao Y, Chen C, Falahpour M, MacNiven KH, Heit G, Sharma V, et al. Effects of Sub-

threshold Transcutaneous Auricular Vagus Nerve Stimulation on Cingulate Cortex and
Insula Resting-state Functional Connectivity. Front Hum Neurosci. 2022;16:862443.

430 13. Garcia-Gonzalez D, Medino-Munoz J, Romero-Elias M, Garcia-Foncillas J, Ruiz-

431 Casado A. Biological mechanisms of cancer-related fatigue in breast cancer survivors after 432 treatment: a scoping review. J Cancer Surviv. 2023.

433 14. Arslan D, Unal Cevik I. Interactions between the painful disorders and the 434 autonomic nervous system. Agri. 2022;34(3):155-65.

435 15. Higgins JPT LT, Chandler J, Tovey D, Churchill R. Methodological Expectations of 436 Cochrane Intervention Reviews: Cochrane; 2016.

437 16. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA
438 2020 explanation and elaboration: updated guidance and exemplars for reporting
439 systematic reviews. BMJ. 2021;372:n160.

440 17. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer
441 Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol.
442 2016;75:40-6.

443 18. Covidence systematic review software. Melbourne, Australia: Veritas Health 444 Innovation.

445 19. Team TE. EndNote. EndNote 20 ed. Philadelphia, PA: Clarivate; 2013.

446 20. Pace R, Pluye P, Bartlett G, Macaulay AC, Salsberg J, Jagosh J, et al. Testing the

reliability and efficiency of the pilot Mixed Methods Appraisal Tool (MMAT) for systematic
mixed studies review. Int J Nurs Stud. 2012;49(1):47-53.

449 21. Schünemann HJ HJ, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Chapter 14:

450 Completing 'Summary of findings' tables and grading the certainty of the evidence. 2023.

451 In: Cochrane Handbook for Systematic Reviews of Interventions version 65 [Internet].

452 <u>www.training.cochrane.org/handbook</u>: Cochrane.

453 22. Tsai HY, Wang CJ, Mizuno M, Muta R, Fetzer SJ, Lin MF. Predictors of cancer-related

454 fatigue in women with breast cancer undergoing 21 days of a cyclic chemotherapy.

455 Worldviews on Evidence-Based Nursing. 2022;19(3):211-8.

456 23. FernÁNdez-Lao C, Cantarero-Villanueva I, DÍAz-RodrÍGuez L, Cuesta-Vargas AI,

457 FernÁNdez-Delas-PeÑAs C, Arroyo-Morales M. Attitudes towards massage modify effects

458 of manual therapy in breast cancer survivors: a randomised clinical trial with crossover

design. European Journal of Cancer Care. 2012;21(2):233-41.

460 Chen S-C, Yeh M-L, Chang H-J, Lin M-F. Music, heart rate variability, and symptom 24. 461 clusters: a comparative study. Supportive Care in Cancer. 2020;28(1):351-60. 462 25. Aoki M, Kuratsune H, Yamamoto S, Hirano T, Hanaeda K, Nishi Y, et al. Autonomic 463 function measurements for evaluating fatigue and quality of life in patients with breast 464 cancer undergoing radiation therapy: a prospective longitudinal study. Radiation Oncology. 465 2023;18(1):171. 466 Uchida S, Kadoi Y, Saito S. Differences in heart rate variability may be related to the 26. 467 appearance of postoperative pain in patients undergoing breast cancer surgery. JA Clinical 468 Reports. 2017;3(1):56. 469 Fagundes CP, Murray DM, Hwang BS, Gouin J-P, Thayer JF, Sollers III JJ, et al. 27. 470 Sympathetic and parasympathetic activity in cancer-related fatigue: more evidence for a 471 physiological substrate in cancer survivors. Psychoneuroendocrinology. 2011;36(8):1137-472 47. 473 28. Yesil H, Eyigor S, Kayikcioglu M, Uslu R, Inbat M, Ozbay B. Is neuropathic pain 474 associated with cardiac sympathovagal activity changes in patients with breast cancer? 475 Neurological Research. 2018;40(4):297-302. 476 29. Guimond A-J, Ivers H, Savard J. Is emotion regulation associated with cancer-related 477 psychological symptoms? Psychology & Health. 2019;34(1):44-63. 478 30. Uchida S, Kadoi Y, Saito S. Effect of Low Dose Remifentanil on Postoperative Pain 479 Relief and Heart Rate Variability in Post-Anaesthesia Care Unit. Turk Anestezi Ve 480 Reanimasyon Dergisi. 2017;45(5):297-302. 481 31. Chuang C-Y, Han W-R, Li P-C, Young S-T. Effects of music therapy on subjective 482 sensations and heart rate variability in treated cancer survivors: a pilot study. 483 Complementary therapies in medicine. 2010;18(5):224-6. 484 32. Masel EK, Huber P, Engler T, Watzke HH. Heart rate variability during treatment of 485 breakthrough pain in patients with advanced cancer: a pilot study. Journal of pain research. 486 2016;9:1215-20. 487 33. Lee Y-H, Chang Y-P, Lee J-T, Lee D-C, Huang E-Y, Lai L-JT. Heart rate variability as an 488 indicator of the beneficial effects of Qigong and mindfulness training on the mind-body 489 well-being of cancer survivors. Supportive Care in Cancer. 2023;31(1):59. 490 Niederer D, Vogt L, Thiel C, Schmidt K, Bernhörster M, Lungwitz A, et al. Exercise 34. 491 Effects on HRV in Cancer Patients. International Journal of Sports Medicine. 2013;34(1):68-492 73. 493 35. Fournié C, Verkindt C, Dalleau G, Bouscaren N, Mohr C, Zunic P, et al. Rehabilitation 494 program combining physical exercise and heart rate variability biofeedback in hematologic 495 patients: a feasibility study. Support Care Cancer. 2022;30(3):2009-16. 496 Murofushi KN, Komazawa M, Murofushi W, Hayakawa S, Ito K, Shimizuguchi T, et al. 36. 497 Preliminary Study on Establishing a Heart Rate Variability-based Method for Objectively 498 Evaluating Bone Metastasis Pain. In Vivo. 2023;37(2):940-7. 499 37. Riesenberg H, Lübbe AS. In-patient rehabilitation of lung cancer patients—a 500 prospective study. Supportive Care in Cancer. 2010;18:877-82. 501 Lee Y-H, Lai G-M, Lee D-C, Tsai Lai L-J, Chang Y-P. Promoting Physical and 38. 502 Psychological Rehabilitation Activities and Evaluating Potential Links Among Cancer-

Related Fatigue, Fear of Recurrence, Quality of Life, and Physiological Indicators in Cancer
Survivors. Integrative Cancer Therapies. 2018;17(4):1183-94.

505 39. Cheng T-C, Lee Y-H, Mar C-L, Huang W-T, Chang Y-P. The health promoting 506 mindfulness or Qigong educational programs for beneficial lifestyle changes of cancer 507 survivors. Journal of Cancer Education. 2020;35:743-50.

40. Burch JB, Ginsberg J, McLain AC, Franco R, Stokes S, Susko K, et al. Symptom
management among cancer survivors: Randomized pilot intervention trial of heart rate
variability biofeedback. Applied psychophysiology and biofeedback. 2020;45:99-108.

511 41. Shaffer F, Ginsberg JP. An Overview of Heart Rate Variability Metrics and Norms.

512 Front Public Health. 2017;5:258.

42. Sammito S, Böckelmann I, editors. Factors influencing heart rate variability.
International Cardiovascular Forum Journal; 2016.

515 43. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, et al. Cardio-

516 oncology rehabilitation to manage cardiovascular outcomes in cancer patients and

survivors: a scientific statement from the American Heart Association. Circulation.2019;139(21):e997-e1012.

- 44. Kuss O, Schumann B, Kluttig A, Greiser KH, Haerting J. Time domain parameters can
 be estimated with less statistical error than frequency domain parameters in the analysis
 of heart rate variability. Journal of electrocardiology. 2008;41(4):287-91.
- 522 45. Ahles TA, Martin JB. Cancer pain: a multidimensional perspective. Hosp J. 1992;8(1-523 2):25-48.
- 524 46. Okuyama T, Akechi T, Kugaya A, Okamura H, Shima Y, Maruguchi M, et al.

525 Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-

rating scale for assessment of fatigue in cancer patients. Journal of pain and symptommanagement. 2000;19(1):5-14.

528 47. Shahid A, Wilkinson K, Marcu S, Shapiro CM. Multidimensional fatigue inventory

529 (MFI). STOP, THAT and one hundred other sleep Scales: Springer; 2011. p. 241-3.

530 48. Stein KD, Jacobsen PB, Blanchard CM, Thors C. Further validation of the

multidimensional fatigue symptom inventory-short form. Journal of pain and symptommanagement. 2004;27(1):14-23.

49. Jang A, Kim DU. The relationship between chemotherapy-induced peripheral


neuropathy and heart rate variability. American Society of Clinical Oncology; 2020.

535 Figure and Table Legend

- 536 Figure 1. PRISMA Flow Diagram
- 537 Table 1. Study Characteristics
- 538 Appendix 1. Full Search Strategy
- 539 Appendix 2. Mixed Methods Appraisal Tool Results

Figure 1. PRISMA Flow Diagram

medRxiv preprint doi: https://doi.org/10.1101/2025.01.08.25320191; this version posted January 8, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



Included studies ongoing (n = 0) Studies awaiting classification (n = 0)

28th December 2024

🔰 covidence

First author (year)	Country	Aim of study	Design	Participants recruited	Heart rate variability measurement details	Key relevant findings
Lee (2018)	Taiwan	To assess the effects of 12 weeks of Qigong exercise or stress management training on fatigue, fear of recurrence, quality of life, and heart rate variability in people who completed cancer treatment at least 1 month prior.	Randomiz ed control trial	99 cancer survivors	5-minute recording seated or lying prone; PPG device; time domain as primary	After 12 weeks of both Qigong and stress management training, fatigue was reduced and increases in SDNN, TP and HF were observed.
Burch (2020)	USA	To assess if heart rate variability biofeedback treatment among cancer survivors can increase HRV coherence and reduce symptoms of pain, stress, fatigue, depression, distress, PTSD, and insomnia relative to control patients in 6 weeks.	Pilot randomize d control trial	38 cancer survivors	15-minute recording, no positioning information mentioned; ECG device; HRV coherence ratio reported as primary	Relative to controls, the intervention group experienced trends toward improvements in stress, distress, fatigue, PTSD, and depression. HRV coherence ratio increased following biofeedback training in the intervention group while no change or decrease in coherence ratio occurred with control group.
Tsai (2021)	Taiwan	To assess what factors may influence the outcome of cancer related fatigue among female breast	Cohort study	109 patients undergoing cancer treatment	15-minute recording, no positioning information given; ECG device;	Anxiety, depression, and symptom distress contributed to cancer related fatigue with symptom distress, anxiety

		cancer patients undergoing chemotherapy			frequency domain as primary	and sleep deprivation consistently high amongst those receiving chemotherapy. No predictive relationship was found between LF/HF ratio and fatigue levels.
Cheng (2019)	Taiwan	To assess if 12 weeks of mindfulness or Qigong training change outcomes for fatigue and HRV in cancer survivors	Randomiz ed control trial	66 cancer survivors	5-minute recording; no positioning information given; PPG device; time domain as primary	Reduced cancer-related fatigue was present in both the mindfulness group and the Qigong group. SDNN and TP values also increased from baseline.
Riesenberg (2009)	German y	To assess if intensive supervised aerobic exercise is efficacious in improving HRV, quality of life, and functional status for patients with lung cancer over a 28-day period in inpatient rehab?	Cohort study	45 patients undergoing cancer treatment	12-minute recording laying down; PPG device; time domain as primary	Exercise capacity and functional status (quality of life, fatigue) improved during rehabilitation. RMSSD increased post intervention.
Chuang (2010)	Taiwan	To assess if music therapy is effective in lowering anxiety, improving mood, and improving HRV when applied for a 2-hour session one time intervention in cancer survivors	Quasi- experimen tal	23 cancer survivors	5-minute recording, no positioning information given; ECG device; frequency domain as primary	Fatigue levels were lower after music therapy. Increase in HF power and decrease in LF/HF ratio and LF power were observed post intervention.

Fernandez- Lao (2011)	Spain	To investigate the immediate effects of myofascial release on HRV and mood state and to assess the attitude towards massage in breast cancer survivors suffering cancer-related fatigue	Crossover randomize d control trial	20 cancer survivors	5min ECG, no positioning information given; ECG device; time domain as primary	Massage leads to an immediate increase in SDNN, RMSSD and HF and an improvement in mood. The impact of massage on cancer- related fatigue is modulated by the attitude of the patient towards massage, however no interaction was reported between belief and SDNN, RMSSD or HF values.
Chen (2019)	Taiwan	To assess the effect of a single music therapy intervention on multiple mood categories and HRV for women actively being treated for breast cancer.	Randomiz ed control trial	100 patients undergoing cancer treatment	5-minute recording, no positioning information given; ECG device; frequency domain as primary	Women who completed single session music intervention reduced symptoms post intervention compared to control group. Higher LF/HF ratio reported at baseline, but no post intervention data was given.
Aoki (2023)	Japan	To assess if HRV would be useful in evaluating fatigue and quality of life of women with breast cancer undergoing radiotherapy.	Cohort study	75 patients undergoing cancer treatment	2-minute recording, sitting; PPG device; frequency domain as primary	Cognitive and physical fatigue were highest at baseline and decreased by midpoint of treatment. Similarly, a decrease in LF/HF ratio was seen by midpoint of treatment.

Masel (2016)	Austria	To assess if HRV a valid representation for subjective pain for patients in palliative care with cancer break through pain.	Pilot study	10 patients undergoing cancer treatment	24-hour recording, no positioning data given; ECG device; frequency domain as primary	Pain reduction was seen post opioid administration. Log LF/HF ratio decreased in patients with >2 point reduction on the NRS.
Lee (2022)	Taiwan	To assess if there is a difference in HRV measures and quality of life measures when given either Qigong, mindfulness intervention or no intervention in cancer survivors at least 1 month out of treatment.	Quasi- experimen tal	125 cancer survivors	5-minute recording, sitting; PPG device; time domain as primary	Both Qigong and mindfulness interventions had short-term effects in improving overall physical and mental health, and quality of life. Increase in SDNN and total power were noted in the short term, but decreased LF was reported in the long term.
Uchida (2017)	Japan	To assess if HRV is predictive of PACU emergent pain within a 12h hour window in post operative breast cancer surgery patients.	Retrospec tive study	20 patients undergoing cancer treatment	No positioning or recording time information given; PPG device; frequency domain as primary	There was no significant difference in pain intensity between the two groups immediately after admission to PACU. Patients in the intervention group required no analgesic agents for at least 12 hours after surgery. Increased HF and decreased LF/HF ratio values were associated with adequate pain intervention.

Fagundes (2011)	USA	To assess if fatigue level is related to HRV or epinepherine at baseline and during/after a social stressor in breast cancer survivors.	Cohort study	109 cancer survivors	Continuous recording, sitting; PPG device; time domain as primary	Higher fatigue was associated with decreased RMSSD values pre and post stressor.
Niederer (2013)	German y	To assess if exercise over a 16-week period improves HRV measures and cancer related fatigue in both cancer survivors and patients undergoing cancer treatment.	Quasi- experimen tal	45 cancer survivors and those undergoing treatment	5-minute recordings, supine; PPG device; frequency domain as primary	Exercise programing improves quality of life and increases total power values. An increase in HF and decrease in LF was also observed post intervention.
Yesil (2018)	Turkey	To assess whether neuropathic pain is associated with changes in cardiac sympathovagal activity in patients with breast cancer.	Cohort study	70 patients undergoing cancer treatment	24-hour recording, no positioning information given; ECG device; time domain as primary	SDNN was lower and LF/HF ratio was higher in patients with neuropathic pain than in those without.
Fournié (2021)	France	To evaluate the feasibility of a 12-week program combining heart rate variability biofeedback and physical exercise in hematologic patients.	Cohort study	20 patients undergoing cancer treatment	5-minute recording, seated with knees at 90°, feet flat on the floor, hands on thighs, palms facing upward, and eyes closed; PPG device; time domain as primary	No changes in fatigue outcome measures noted despite a trend towards decreasing general/physical fatigue. SDNN and RMSSD did not change over time, but increased LF and HRV coherence ratio were noted.

Murofushi (2023)	Japan	To assess if HRV can provide an objective measure for bone metastasis pain during a period of radiotherapy.	Pilot study	11 patients undergoing cancer treatment	24-hour recording, no positioning information given; PPG device; frequency domain as primary	For all samples, the NRS score showed no significant relationship with mean LF/HF ratio and HF. In patients with an NRS ≥4, the NRS score was significantly associated with LF/HF
Guimond (2018)	Canada	To assess if measures of emotional regulation are associated with measures of psychological symptoms in patients with breast cancer receiving radiotherapy.	Cross- sectional	81 patients undergoing cancer treatment	5-minute recording, no positioning information given; PPG device; time domain as primary	ratio but not HF. Low emotional regulation was marginally associated with increased depression and fatigue between timepoints. HF was not associated with symptom change.
Uchida (2017)	Japan	To assess if low dose Remifentanil effects post operative pain and HRV in breast cancer surgery patients.	Retrospec tive study	20 patients undergoing cancer treatment	No positioning or recording time information given; PPG device; frequency domain as primary	After Remifentanil administration, the value of the NRS decreased. There were no significant differences in HF and LF/HF ratio was found between groups.

Legend:

PPG= photoplethysmogram SDNN= standard deviation of the normal-to-normal interval TP= total power HF= high frequency power

PTSD= post-traumatic stress syndrome HRV= heart rate variability ECG=electrocardiogram LF/HF ratio= low frequency/high frequency ratio

RMSSD = square root of mean squared differences of successive normal-to-normal intervals NRS= numeric rating scale LF= low frequency

PACU= post anesthesia care unit

APA PsychInfo Search

#	Query ility Information and Tips	Results
	rch History	
S1	DE "Heart Rate Variability"	3,0
S2	TI ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR AB ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR AB ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR AB ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR KW ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR KW ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*)))	30,2
S3	(DE "Parasympathetic Nervous System") OR (DE "Autonomic Nervous System")	7,6
S4	TI (activit* or function* or tone*) OR AB (activit* or function* or tone*) OR KW (activit* or function* or tone*)	1,165,6
S5	TI ((((vegetative or visceral or parasympathetic or autonomic) N2 nervous) and (activit* or function* or tone*))) OR AB ((((vegetative or visceral or parasympathetic or autonomic)	3,2
S6	DE "Vagus Nerve"	2,
S7	TI ((((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom*)) OR AB ((((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom*)) OR KW ((((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom*))	4,
S8	DE "Electrocardiography" AND (TI (variab*) OR AB (variab*) OR KW (variab*))	1,0
S9	TI (((Electrocardiogra* or EKG# or ECG# or (Monitoring NO Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra*) and variab*)) OR AB (((Electrocardiogra* or EKG# or ECG# or (Monitoring NO Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra*) and variab*)) OR AB (((Electrocardiogra* or EKG# or ECG# or (Monitoring NO Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra*) and variab*)) OR KW (1,2
S10	TI ((Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*))) OR AB ((Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*))) OR KW ((Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*)))	3,
S11	S3 AND S4	4,
S12	S1 OR S2 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11	39,
S13	((DE "Pain") OR (DE "Acute Pain")) OR (DE "Pain Measurement" OR DE "Pain Thresholds")	53,
S14	TI (((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*))) OR AB (((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*))) OR KW (((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*))) OR KW (((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*))) OR KW (((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*)))	
S15	TI pain* OR AB pain* OR KW pain*	128,
S16	DE "Fatigue"	14,
S17	TI ((Fatigu* OR Lassitude)) OR AB ((Fatigu* OR Lassitude))OR KW ((Fatigu* OR Lassitude))	31,
S18 v preprint d	TI (((small NO (fibre* OR fiber*) NO neuropath*) OR erythermalgia* OR erythromelalgia*)) OR AB (((small NO (fibre* OR fiber*) NO neuropath*) OR erythermalgia* OR oi: hepst/home/algia*01/20R3KW/ ወደርናናልበ NO:(რውლን የአውምን አውን በአውምን አውን በሚያን የመንግስ የመንግስ የመንግስ የመንግስ የመንግስ የመንግስ የ certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. TI ((sciatic NO (palls*igMslession/@RNneuralgia/OR neuralgia-neuritide* OR neuropath* OR neurit#s))) OR AB ((sciatic NO (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR	
S19	TI ((sciatic N0 (pals* OR lesion OR neuralgiallORedevinadgianeuritides OR neuropath* OR neurit#s))) OR AB ((sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR	
S20	S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19	162,
S21	DE "Neoplasms" OR DE "Benign Neoplasms" OR DE "Breast Neoplasms" OR DE "Endocrine Neoplasms" OR DE "Leukemias" OR DE "Melanoma" OR DE "Metastasis" OR DE "Nervous System Neoplasms" OR DE "Terminal Cancer"	62,
S22	(TI ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR melanoma* OR hodgkin* OR "multiple osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leu##emi* OR erythroleu##em* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastas#s OR metastatic OR carcinoid* OR neupolastoma* OR "Pleuropulmonary OR sezary Syndrome" OR Retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR pendymoma* OR thumo#r* OR oncol*)) OR AB ((cancer OR cancers OR cancerous OR carcinoma* OR hyphosarcoma* OR hepatocarcinoma* OR "hepatocarcinoma* OR "nelionosarcoma* OR chondrosarcoma* OR hyphosarcoma* OR hepatocarcinoma* OR neoplas* OR medalomyosarcoma* OR leu##emi* OR erythroleu##em* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR neoplas* OR neoplas* OR metastas#s OR metastatic OR carcinoid* OR neuroblastoma* OR "Nycosis Fungoides" OR "Sezary Syndrome" OR Retinoblastoma* OR hepatocarcinoma* OR redulloblastoma* OR metastatic OR carcinoid* OR neuroblastoma* OR "Pleuropulmonary Blastomas" OR glioblastoma* OR plenohymosarcoma* OR thumoma* OR medulloblastoma* OR meningioma* OR cancers OR cancers OR cancers OR cancers OR carcinoma* OR Repervolustoma* OR medulloblastoma* OR meningioma* OR cancers O	103,
S23	S21 OR S22	105,

S24

Friday, November 10, 2023 5:17:46 PM

CINAHL Search

Thursday, November 09, 2023 4:36:34 PM

#	Query	Results
S26	S12 AND S21 AND S25	55
S25	S22 OR S23 OR S24	988,40
S24	MW ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leuk#emi* OR erythroleuk#em* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastas#s OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR Retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastoma* OR glioblastoma* OR glioma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumo#r* OR oncol*))	716,4
S23	TI ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR echondrosarcoma* OR neoplas* OR malignan* OR metastas OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR Retinoblastoma* OR pheochromocytoma* OR medulloblastoma* OR meningioma* OR choriocarcinoma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pheochroma* OR thymoma* OR theorem a* OR theorem a* OR medulloblastoma* OR meningioma* OR cancers OR cancerous OR carcinoma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pheochroma* OR thymoma* OR tumo#* OR oncol*)) OR AB (cancer OR cancers OR cancerous OR carcinoma* OR rhabdomyosarcoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chordrosarcoma* OR rhabdomyosarcoma* OR hepatocarcinoma* OR carcinosarcoma* OR glioblastoma* OR pheochromocytoma* OR medulloblastoma* OR meningioma* OR cancers OR cancerous OR carcinoma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR lymphoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chordrosarcoma* OR rhabdomyosarcoma* OR leuk#emi* OR erythroleuk#em* OR lymphoma* OR melanoma* OR histiocytoma* OR thymoma* OR tumo#* OR oncol*)) OR AB (cancer OR cancers OR cancerous OR carcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR soteosarcoma* OR chordrosarcoma* OR rhabdomyosarcoma* OR leuk#emi* OR erythroleuk#em* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastas#s OR metastatic OR carcinoid* OR neuroblastoma* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR choriocarcinoma* OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR Retinoblastoma* OR pheochromocytoma* OR me	820,51
S22	(MH "Neoplasms+")	662,99
S21	S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20	430,30
	TI ((sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neurit#s))) OR AB ((sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neurit#s))) OR AB ((sciatic N0 (pals* OR lesion OR neuralgia OR neuritide* OR neuropath* OR neurit#s))) OR MW ((sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia OR neuropath* OR neurit#s))) OR MW ((sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia OR neuralgia - neuritide* OR neuropath* OR neurit#s))) OR MW ((sciatic N0 (pals* OR lesion OR neuralgia OR neuralgia - neuritide* OR neuropath* OR neurit#s)))	g
	TI (((small N0 (fibre* OR fiber*) N0 neuropath*) OR erythermalgia* OR erythromelalgia*)) OR AB (((small N0 (fibre* OR fiber*) N0 neuropath*) OR erythermalgia* OR erythromelalgia*)) OR MW (((small N0 (fibre* OR fiber*) N0 neuropath*) OR erythermalgia* OR erythromelalgia*))	60
S18	(MH "Small Fiber Neuropathy")	5
S17	TI ((Fatigu* OR Lassitude)) OR AB ((Fatigu* OR Lassitude))OR MW ((Fatigu* OR Lassitude))	57,55
S16	(MH "Fatigue")	21,99
S15	TI pain* OR AB pain* OR MW pain*	383,64
S14	TI (((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*))) OR AB (((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*))) OR MW (((Acute or radia*) N1 (Ache* or hurt* or aching or suffer*)))	1,11
S13	(MH "Pain") OR (MH "Acute Pain (Saba CCC)") OR (MH "Acute Pain Control (Saba CCC)") OR (MH "Pain Measurement") OR (MH "Pain Threshold") OR (MH "Cancer Pain")	125,74
S12	S1 OR S2 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11	85,47
<u> </u>	TI ((Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*))) OR AB ((Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or activit* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or function* or tone* or electrophysiolog*))) OR MW ((Cardiac N2 (control* or function* or funct	. 16,08
reprin S₩as	TI (((Electrocardiogra* or EKG# or EKG# or (Monitoring NO Holter) or Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra*) and variab*)) OR AB (((Electrocardiogra* or EKG# or EKG# or polarcardiogra*) and variab*)) OR AB (((Electrocardiogra* or EKG# or EKG# or polarcardiogra*) and variab*)) OR AB (((Electrocardiogra* or EKG# or EKG# or polarcardiogra*) and variab*)) OR AB (((Electrocardiogra* or EKG# or experiment) or vector of the provident holder for this preprint of the	4,15
S9	(MH "Electrocardiography") AND (TI (variab*) OR AB (variab*) OR MW (variab*))	3,62
<u>v</u> 1	TI ((((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom*)) OR AB ((((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom*)) OR MW ((((Cranial or vagus or vagal or tenth or pneumogastric or x) N1 (nerve* or nervus or tone)) or vagatom*))	6,79
	(MH "Vagus Nerve")	1,5
S6	TI ((((vegetative or visceral or parasympathetic or autonomic) N2 nervous) and (activit* or function* or tone*))) OR AB ((((vegetative or visceral or parasympathetic or autonomic) N2 nervous) and (activit* or function* or tone*))) OR MW ((((vegetative or visceral or parasympathetic or autonomic) N2 nervous) and (activit* or function* or tone*))) OR MW ((((vegetative or visceral or parasympathetic or autonomic) N2 nervous) and (activit* or function* or tone*))) OR MW ((((vegetative or visceral or parasympathetic or autonomic) N2 nervous) and (activit* or function* or tone*)))	2,4
S5	S3 AND S4	3,0
	TI (activit* or function* or tone*) OR AB (activit* or function* or tone*) OR MW (activit* or function* or tone*)	992,6
	(MH "Parasympathetic Nervous System" OR MH "Autonomic Nervous System")	5,9
S2	TI ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR AB ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or Sinus*) N1 Arrhythmi*))) OR AB ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR AB ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR MW ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR MW ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR MW ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or ((Respirat* or Sinus*) N1 Arrhythmi*))) OR MW ((((Cardia* or Heart or pulse) N1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) N1 Arrhythmi*)))	
	(MH "Heart Rate") AND (TI(variab*) OR AB(variab*) OR MW(variab*))	671
JT	(init heart nate / hive (hivanae / on Ab(valiae / on inivity) valiae //	6,74

Cochrane Search

Search Name: Hear Rate Variability- Cancer Patients-Draft 7

Date Run: 10/11/2023 11:31:02

Comment:

ID Search Hits

#1 MeSH descriptor: [Heart Rate] this term only 24584

#2 (variab*):ti,ab,kw 121731

#3 #1 AND #2 4455

#4 ((((Cardia* or Heart or pulse) NEAR/1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) NEAR/1 Arrhythmi*))):ti 4960

#5 MeSH descriptor: [Parasympathetic Nervous System] this term only 256

#6 MeSH descriptor: [Autonomic Nervous System] this term only 1497

#7 (activit* or function* or tone*):ti,ab,kw 483609

#8 (#5 OR #6) AND #7 1163

#9 ((((vegetative or visceral or parasympathetic or autonomic) NEAR/2 nervous) and (activit* or function* or tone*))):ti,ab,kw 3058

#10 MeSH descriptor: [Vagus Nerve] this term only 486

#11 ((((Cranial or vagus or vagal or tenth or pneumogastric or x) NEAR/1 (nerve* or nervus or tone)) or vagatom*)):ti,ab,kw 2691

#12 MeSH descriptor: [Electrocardiography] this term only 8896

#13 #12 AND #2 1094

#14 (((Electrocardiogra* or EKG? or ECG? or (Monitoring NEAR/0 Holter) or
 Vectercardiogra* or Vecter-cardiogra* or polarcardiogra* or polar-cardiogra*) and
 variab*)):ti 39

#15 ((Cardiac NEAR/2 (control* or activit* or function* or tone* or electrophysiolog*))):ti,ab,kw 7981

#16 #3 OR #4 OR #8 OR #9 OR #10 OR #11 OR #13 OR #14 OR #15 20284

- #17 MeSH descriptor: [Pain] this term only 20160
- #18 MeSH descriptor: [Acute Pain] this term only 1192
- #19 MeSH descriptor: [Pain Measurement] this term only 24490
- #20 MeSH descriptor: [Pain Threshold] this term only 2141
- #21 MeSH descriptor: [Cancer Pain] this term only 471
- #22 (((Acute or radia*) NEAR/1 (Ache* or hurt* or aching or suffer*))):ti,ab,kw 240
- #23 (pain*):ti,ab,kw 240777
- #24 MeSH descriptor: [Fatigue] this term only 8405
- #25 ((Fatigu* or Lassitude)):ti,ab,kw 44423
- #26 MeSH descriptor: [Small Fiber Neuropathy] this term only 23

#27 (((small NEAR/0 (fibre* or fiber*) NEAR/0 neuropath*) or erythermalgia* or erythromelalgia*)):ti,ab,kw 28

#28 MeSH descriptor: [Sciatic Neuropathy] this term only 9

#29 ((sciatic NEAR/0 (pals* or lesion or neuralgia or neuralgia-neuritide* or neuropath* or neurit?s))):ti,ab,kw0

#30 {OR #17-#29} 272529

#31 MeSH descriptor: [Neoplasms] explode all trees 113268

#32 ((cancer or cancers or cancerous or carcinoma* or adenocarcinoma* or hepatocarcinoma* or carcinosarcoma* or sarcoma* or histiocytoma* or fibrosarcoma* or osteosarcoma* or chondrosarcoma* or lymphosarcoma* or rhabdomyosarcoma* or leuk?emi* or erythroleuk?em* or lymphoma* or melanoma* or hodgkin* or "multiple myeloma" or mesothelioma* or neoplas* or malignan* or metastas?s or metastatic or carcinoid* or neuroblastoma* or "Mycosis Fungoides" or "Sezary Syndrome" or Retinoblastoma* or pheochromocytoma* or nephroblastoma* or choriocarcinoma* or "Pleuropulmonary Blastoma" or "Pleuropulmonary Blastomas" or glioblastoma* or glioma* or astrocytoma* or ependymoma* or medulloblastoma* or meningioma* or craniopharyngioma* or myelodysplastic or myeloproliferative or macroglobulinemi* or macroglobulinaemi* or pineoblastoma* or thymoma* or tumo?r* or oncol*)):ti,ab,kw 288103

200100

#33 {OR #31-#32} 293001

#34 #16 AND #30 AND #33 229

(which #21	prep @tueny https://doi.org/10.1101/2025.01.08.25320191; this version posted January 8, 2025. The copyright holder for this Res n was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. #8 AND #17 AND #20 All rights reserved. No reuse allowed without permission.	utts 5154
#20	#18 OR #19	7599837
	cancer:ti,ab,kw OR cancers:ti,ab,kw OR cancerous:ti,ab,kw OR carcinoma*:ti,ab,kw OR	
	adenocarcinoma*:ti,ab,kw OR hepatocarcinoma*:ti,ab,kw OR carcinosarcoma*:ti,ab,kw OR	
	sarcoma*:ti,ab,kw OR histiocytoma*:ti,ab,kw OR fibrosarcoma*:ti,ab,kw OR	
	osteosarcoma*:ti,ab,kw OR chondrosarcoma*:ti,ab,kw OR lymphosarcoma*:ti,ab,kw OR	
	rhabdomyosarcoma*:ti,ab,kw OR leuk\$emi*:ti,ab,kw OR erythroleuk\$em*:ti,ab,kw OR	
	lymphoma*:ti,ab,kw OR melanoma*:ti,ab,kw OR hodgkin*:ti,ab,kw OR 'multiple	
	myeloma':ti,ab,kw OR mesothelioma*:ti,ab,kw OR neoplas*:ti,ab,kw OR malignan*:ti,ab,kw OR	
	metastasis:ti,ab,kw OR metastases:ti,ab,kw OR metastatic:ti,ab,kw OR carcinoid*:ti,ab,kw OR	
	neuroblastoma*:ti,ab,kw OR 'mycosis fungoides':ti,ab,kw OR 'sezary syndrome':ti,ab,kw OR	
	retinoblastoma*:ti,ab,kw OR pheochromocytoma*:ti,ab,kw OR nephroblastoma*:ti,ab,kw OR	
	choriocarcinoma*:ti,ab,kw OR 'pleuropulmonary blastoma':ti,ab,kw OR 'pleuropulmonary	
	blastomas':ti,ab,kw OR glioblastoma*:ti,ab,kw OR glioma*:ti,ab,kw OR astrocytoma*:ti,ab,kw	
	OR ependymoma*:ti,ab,kw OR medulloblastoma*:ti,ab,kw OR meningioma*:ti,ab,kw OR	
	craniopharyngioma*:ti,ab,kw OR myelodysplastic:ti,ab,kw OR myeloproliferative:ti,ab,kw OR	
"40	macroglobulinemi*:ti,ab,kw OR macroglobulinaemi*:ti,ab,kw OR pineoblastoma*:ti,ab,kw OR	054 4000
#19	thymoma*:ti,ab,kw OR tumo\$r*:ti,ab,kw OR oncol*:ti,ab,kw	6514366
#18 #17	'neoplasm'/exp	6290897
#17	#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16	1736879
#16	(sciatic NEAR/1 (pals* OR lesion OR neuralgia OR 'neuralgia neuritide*' OR neuropath* OR neurit\$s)):ti,ab,kw	667
#10	((small NEAR/1 (fibre* OR fiber*) NEAR/1 neuropath*):ti,ab,kw) OR erythermalgia*:ti,ab,kw OR	007
#15	erythromelalgia*:ti,ab,kw	3549
#14	'small fiber neuropathy'/de OR 'sciatic neuropathy'/de	2841
#13	fatigu*:ti,ab,kw OR lassitude:ti,ab,kw	216159
#12	'fatigue'/de	281217
#11	pain*:ti,ab,kw	1343325
#10	((acute OR radia*) NEAR/2 (ache* OR hurt* OR aching OR suffer*)):ti,ab,kw	11296
#9	'pain'/de OR 'pain measurement'/de OR 'pain threshold'/de OR 'cancer pain'/de	445850
#8	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7	521833
#7	(cardiac NEAR/3 (control* OR activit* OR function* OR tone* OR electrophysiolog*)):ti,ab,kw	122428
	('electrocardiography'/de OR 'electrocardiogram'/de) AND variab*:ti,ab,kw OR	
	((electrocardiogra*:ti,ab,kw OR ekg\$:ti,ab,kw OR ecg\$:ti,ab,kw OR ((monitoring NEAR/1	
	holter):ti,ab,kw) OR vectercardiogra*:ti,ab,kw OR 'vecter cardiogra*':ti,ab,kw OR	
#6	polarcardiogra*:ti,ab,kw OR 'polar cardiogra*':ti,ab,kw) AND variab*:ti,ab,kw)	35182
	(((cranial OR vagus OR vagal OR tenth OR pneumogastric OR x) NEAR/2 (nerve* OR nervus OR	
#5	tone)):ti,ab,kw) OR vagatom*:ti,ab,kw	57184
	(((vegetative OR visceral OR parasympathetic OR autonomic) NEAR/3 nervous):ti,ab,kw) AND	
#4	(activit*:ti,ab,kw OR function*:ti,ab,kw OR tone*:ti,ab,kw)	23470
	('autonomic nervous system'/de OR 'parasympathetic nervous system physiology'/de) AND	
#3	(activit*:ti,ab,kw OR function*:ti,ab,kw OR tone*:ti,ab,kw)	28746
	(((cardia* OR heart OR pulse) NEAR/2 (atria* OR chronotro* OR period OR rate* OR	
	control*)):ti,ab,kw) OR heartbeat*:ti,ab,kw OR 'heart beat*':ti,ab,kw OR (((respirat* OR sinus*)	
#2	NEAR/2 arrhythmi*):ti,ab,kw)	325390

70329

#2 NEAR/2 arrhythmi*):ti,ab,kw)#1 ('heart rate'/exp OR 'heart rate') AND variab*:ti,ab,kw

10-Nov-23

10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23 10-Nov-23

10-Nov-23

10-Nov-23

10-Nov-23

10-Nov-23

10-Nov-23 10-Nov-23

Scopus Search

1,752 results

(TITLE-

ABS((((vegetative OR visceral OR parasympathetic OR autonomic) W/2 nervou s) AND (activit* OR function* OR tone*))) OR TITLE-ABS

((((cardia* OR heart OR pulse) W/1 (atria* OR chronotro* OR period OR rate * OR control*)) OR heartbeat* OR heart-

beat* OR ((respirat* OR sinus*) W/1 arrhythmi*))) OR TITLE-ABS

((((cranial OR vagus OR vagal OR tenth OR pneumogastric OR x) W/1 (nerv e* OR nervus OR tone)) OR vagatom*)) OR TITLE-ABS

(((electrocardiogra* OR ekg OR ecg

OR ekgs OR ecgs OR (monitoring W/0 holter) OR vectercardiogra* OR vectercardiogra* OR polarcardiogra* OR polar-cardiogra*) AND variab*))

AND

TITLE-ABS

((acute OR radia*) W/1 (ache* OR hurt* OR aching OR suffer*)) OR TITLE-ABS (pain*) OR TITLE-ABS ((fatigu* OR lassitude)) OR TITLE-ABS

(((small W/0 (fibre* OR fiber*) W/0 neuropath*) OR erythermalgia* OR erythro melalgia*)) OR TITLE-ABS

((sciatic W/0 (pals* OR lesion OR neuralgia OR neuralgia-

neuritide* OR neuropath* OR neuritis OR neurites)))

AND

TITLE-

ABS ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fi brosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rh abdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* O R medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineobl astoma* OR thymoma* OR tumor* OR tumour* OR oncol*)))

6,999 results

(TITLE-ABS-KEY ((((vegetative OR visceral OR parasympathetic OR autonomic)) W/2 nervo us) AND (activit* OR function* OR tone*))) OR TITLE-ABS-KEY ((((cardia* OR heart OR pulse)) W/1 (atria* OR chronotro* OR period OR rate* OR control*)) OR heartbeat* OR heartbeat* OR ((respirat* OR sinus*)) W/1 arrhythmi*))) OR TITLE-ABS-KEY (((cranial OR vagus OR vagal OR tenth OR pneumogastric OR x) W/1 (nerve* OR nervus OR tone)) OR vagatom*)) OR TITLE-ABS-KEY (((electrocardiogra* OR ekg OR ecg OR ekgs OR ecgs OR (monitoring W/0 holter) OR vectercardiogra* OR vectercardiogra* OR polarcardiogra* OR polar-cardiogra*) AND variab*)) AND TITLE-ABS-

KEY ((acute OR radia*) W/1 (ache* OR hurt* OR aching OR suffer*)) OR TIT LE-ABS-KEY (pain*) OR TITLE-ABS-KEY ((fatigu* OR lassitude)) OR TITLE-ABS-KEY (((small W/0 (fibre* OR fiber*) W/0 neuropath*) OR erythermalgia* OR er ythromelalgia*)) OR TITLE-ABS-KEY ((sciatic W/0 (pals* OR lesion OR neuralgia OR neuralgia-

neuritide* OR neuropath* OR neuritis OR neurites)))

AND

TITLE-ABS-

KEY ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fi brosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rh abdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* O R medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineobl astoma* OR thymoma* OR tumor* OR tumour* OR oncol*)))

Search Strategy from ProQuest

November 10 2023 18:34



SEAF	(which was not certified by peer review)	/2025.01.08.25320191; this version posted January 8, 2025. The copyright holder is the author/funder, who has granted medRxiv a license to display the preprint in I rights reserved. No reuse allowed without permission.	for this preprint perpetuity.
Set N		Databases	Results
S1	noft((((Cardia* or Heart or pulse) NEAR/1 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) NEAR/1 Arrhythmi*)))	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	754569
S3	noft((((vegetative or visceral or parasympathetic or autonomic) NEAR/2 nervous) and (activit* or function* or tone*)))	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	53855
S4	MAINSUBJECT.EXACT("Heart rate")	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	315187



Political Science Abstracts

S6 me	JRAFt6(((Grandel Apply Agus of 0.1101 (Wagal Vortentified by peer review) Al pneumogastric or x) NEAR/1 (nerve* or nervus or tone)) or vagatom*))	Abl/NFORM Collections Academia Video, Ozline Apl/Cataloger SAmerican Period Visions Academia Video, Ozline Apl/Cataloger Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	fð 969 f reprint þerpetuity.
S7	MAINSUBJECT.EXACT("Heart rate") AND noft(variab*)	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	56797
S8	noft(((Electrocardiogra* or EKG? or ECG? or (Monitoring NEAR/0 Holter) or Vectercardiogra* or Vecter- cardiogra* or polarcardiogra* or polar-cardiogra*) and variab*))	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	39998
S9	noft((Cardiac NEAR/2 (control* or activit* or function* or tone* or electrophysiolog*)))	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National	161785



me	dRxiv preprint doi: https://doi.org/10.1101 (which was not certified by peer review) Al	Security Archiver: Dissertations & Theres, @ 2019 Versity of holder in the anti-control of the Booker neuroscient of the Periodic Stream, Healthcare NewsWatch, Gender Watch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	for this preprint perpetuity.
S10	[S1] OR [S3] OR [S4] OR [S6] OR [S7] OR [S8] OR [S9]	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts These databases are searched for part of your query.	996678
S12	MAINSUBJECT.EXACT("Pain") OR MAINSUBJECT.EXACT("Pain management")	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	860675
S13	noft(((Acute or radia*) NEAR/1 (Ache* or hurt* or aching or suffer*)) OR pain*)	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare	7823310



me	dRxiv preprint doi: https://doi.org/10.1101 (which was not certified by peer review) Al	Administration Database in Music Periodicals Database yright holder Producest Order Mar Perara Produces in Second Second Produces (Order Produces Allowed Without permission Clobal, Producest Historical Newspapers: Chicago Defender, Producest Historical Newspapers: New York Amsterdam News, Producest Historical Newspapers: New York Tribune, Producest Historical Newspapers: New York Tribune, Producest Historical Newspapers: The Baltimore Afro-American, Producest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	for this preprint perpetuity.
S14	MAINSUBJECT.EXACT("Fatig ue") OR noft((Fatigu* or Lassitude))	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	805916
S15	noft(((small NEAR/0 (fibre* or fiber*) NEAR/0 neuropath*) or erythermalgia* or erythromelalgia*)) OR noft((sciatic NEAR/0 (pals* or lesion or neuralgia or neuralgia-neuritide* or neuropath* or neurit?s)))	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	6879
S16	[S12] OR [S13] OR [S14] OR [S15]	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News,	8558603



me	dRxiv preprint doi: https://doi.org/10.1101 (which was not certified by peer review) Al	BroQuest Historical Newspapersi New Yerkozijowe op ProQuest is district of Newspapers of the det Riv Tilianse, of the Quest preprint in Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts These databases are searched for part of your query.	for this preprint perpetuity.
S17	MAINSUBJECT.EXACT("Canc er") OR noft((cancer or cancers or cancerous or carcinoma* or adenocarcinoma* or adenocarcinoma* or carcinosarcoma* or sarcoma* or histiocytoma* or fibrosarcoma* or osteosarcoma* or chondrosarcoma* or lymphosarcoma* or leuk?emi* or erythroleuk?em* or lymphoma* or melanoma* or hodgkin* or "multiple myeloma" or mesothelioma* or neoplas* or malignan* or metastas?s or metastatic or carcinoid* or neuroblastoma* or "Mycosis Fungoides" or "Sezary Syndrome" or Retinoblastoma* or onephroblastoma* or pheochromocytoma* or nephroblastoma* or choriocarcinoma* or "Pleuropulmonary Blastomas" or glioblastoma* or glioma* or astrocytoma* or medulloblastoma* or meningioma* or craniopharyngioma* or meningioma* or craniopharyngioma* or myelodysplastic or myeloproliferative or macroglobulinemi* or pineoblastoma* or thymoma* or tumo?r* or oncol*))	ABJ/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, Gender/Watch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Arribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	14565453
S18	[S10] AND [S16] AND [S17]	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries	6850



me	dRxiv preprint doi: https://doi.org/10.1101 (which was not certified by peer review) Al	American Beriodicals veASEA: Aquatica Sciences and Episheries derived by the second transformer and the second transformer allowed without permission. Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts	for this preprint berpetuity.
S19	([S10] AND [S16] AND [S17]) AND stype.exact("Dissertations & Theses")	ABI/INFORM Collection, Academic Video Online, AFI Catalog, American Periodicals, ASFA: Aquatic Sciences and Fisheries Abstracts, Black Studies Center, Business Market Research Collection, Coronavirus Research Database, Digital National Security Archive, Dissertations & Theses @ University of Miami, Early Modern Books, Ebook Central, ERIC, Ethnic NewsWatch, GenderWatch, Global Newsstream, Healthcare Administration Database, Music Periodicals Database, ProQuest Civil War Era, ProQuest Dissertations & Theses Global, ProQuest Historical Newspapers: Chicago Defender, ProQuest Historical Newspapers: New York Amsterdam News, ProQuest Historical Newspapers: New York Tribune, ProQuest Historical Newspapers: Philadelphia Tribune, ProQuest Historical Newspapers: The Baltimore Afro-American, ProQuest Historical Newspapers: The New York Times with Index, PTSDpubs, Publicly Available Content Database, Research Library, SciTech Premium Collection, Sociological Abstracts, Teatro Español del Siglo de Oro, Worldwide Political Science Abstracts These databases are searched for part of your query.	91



Terms and Conditions Contact ProQuest



Medline Search

Ovid MEDLINE(R) ALL <1946 to November 08, 2023>

1 exp Heart Rate/ and variab*.ti,ab,kf,kw. (((Cardia* or Heart or pulse) adj2 (Atria* or Chronotro* or period or rate* or control*)) or Heartbeat* or heart-beat* or ((Respirat* or Sinus*) adj2	31825
2 Arrhythmi*)).ti,ab,kf,kw.	224772
(Parasympathetic Nervous System/ or Autonomic Nervous System/) and	46600
3 (activit* or function* or tone*).ti,ab,kf,kw. (((vegetative or visceral or parasympathetic or autonomic) adj3 nervous) and	16638
4 (activit* or function* or tone*)).ti,ab,kf,kw.	14958
5 Vagus Nerve/	23164
(((Cranial or vagus or vagal or tenth or pneumogastric or x) adj2 (nerve* or	
6 nervus or tone)) or vagatom*).ti,ab,kf,kw.	38737
(Electrocardiography/ and variab*.ti,ab,kf,kw.) or ((Electrocardiogra* or EKG? or ECG? or (Monitoring adj1 Holter) or Vectercardiogra* or Vecter-cardiogra*	
7 or polarcardiogra* or polar-cardiogra*) and variab*).ti,ab,kf,kw.	22731
(Cardiac adj3 (control* or activit* or function* or tone* or	
8 electrophysiolog*)).ti,ab,kf,kw.	80144
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8	360405
Pain/ or Acute Pain/ or Pain Measurement/ or Pain Threshold/ or Cancer	
10 Pain/	233972
11 ((Acute or radia*) adj2 (Ache* or hurt* or aching or suffer*)).ti,ab,kf,kw.	6974
12 pain*.ti,ab,kf,kw.	871995
13 Fatigue/	35584
14 (Fatigu* or Lassitude).ti,ab,kf,kw.	130599
15 Small Fiber Neuropathy/ ((small adj1 (fibre* or fiber*) adj1 neuropath*) or erythermalgia* or	326
16 erythromelalgia*).ti,ab,kf,kw.	2122
17 Sciatic Neuropathy/	2261
(sciatic adj1 (pals* or lesion or neuralgia or neuralgia-neuritide* or	
18 neuropath* or neurit?s)).ti,ab,kf,kw.	451
19 or/10-18	1044216
20 exp Neoplasms/	3895438

(cancer or cancers or cancerous or carcinoma* or adenocarcinoma* or hepatocarcinoma* or carcinosarcoma* or sarcoma* or histiocytoma* or fibrosarcoma* or osteosarcoma* or chondrosarcoma* or lymphosarcoma* or rhabdomyosarcoma* or leuk?emi* or erythroleuk?em* or lymphoma* or melanoma* or hodgkin* or "multiple myeloma" or mesothelioma* or neoplas* or malignan* or metastas?s or metastatic or carcinoid* or neuroblastoma* or "Mycosis Fungoides" or "Sezary Syndrome" or Retinoblastoma* or pheochromocytoma* or nephroblastoma* or choriocarcinoma* or "Pleuropulmonary Blastoma" or "Pleuropulmonary Blastomas" or glioblastoma* or glioma* or astrocytoma* or ependymoma* or medulloblastoma* or meningioma* or craniopharyngioma* or myelodysplastic or myeloproliferative or macroglobulinemi* or macroglobulinaemi* or pineoblastoma* or thymoma* or tumo?r* or 21 oncol*).ti,ab,kf,kw. 4649704 22 20 or 21 5325255 23 9 and 19 and 22 1802

Entitlemen Dat	tabase #	Search Query	Results	Date Run
		(((((vegetative OR visceral OR parasympathetic OR autonomic) NEAR/2 nervous) AND (
		activit* OR function* OR tone*))) OR ((((cardia* OR heart OR pulse) NEAR/1 (atria*		
		OR chronotro* OR period OR rate* OR control*)) OR heartbeat* OR heart-beat* OR ((
		respirat* OR sinus*) NEAR/1 arrhythmi*))) OR ((((cranial OR vagus OR vagal OR tenth		
		OR pneumogastric OR x) NEAR/1 (nerve* OR nervus OR tone)) OR vagatom*)) OR (((
		electrocardiogra* OR ekg OR ecg OR ekgs OR ecgs OR (monitoring NEAR/O holter) OR		
	ah of Sci	vectercardiogra* OR vecter-cardiogra* OR polarcardiogra* OR polar-cardiogra*) AND variab* 1))) (Title)	69800	Fri Nov 10 2023 14:55:21 GMT-0500 (Eastern Standard T
wos.sei. we		(((((vegetative OR visceral OR parasympathetic OR autonomic) NEAR/2 nervous) AND (05000	
		activit* OR function* OR tone*))) OR ((((cardia* OR heart OR pulse) NEAR/1 (atria*		
		OR chronotro* OR period OR rate* OR control*)) OR heartbeat* OR heart-beat* OR ((
		respirat* OR sinus*) NEAR/1 arrhythmi*))) OR ((((cranial OR vagus OR vagal OR tenth		
		OR pneumogastric OR x) NEAR/1 (nerve* OR nervus OR tone)) OR vagatom*)) OR (((
		electrocardiogra* OR ekg OR ecg OR ekgs OR ecgs OR (monitoring NEAR/O holter) OR		
		vectercardiogra* OR vecter-cardiogra* OR polarcardiogra* OR polar-cardiogra*) AND variab*		
- WOS.SCI: We	eb of Sci	2))) (Abstract)	229307	Fri Nov 10 2023 14:55:32 GMT-0500 (Eastern Standard T
		(((((vegetative OR visceral OR parasympathetic OR autonomic) NEAR/2 nervous) AND (
		activit* OR function* OR tone*))) OR ((((cardia* OR heart OR pulse) NEAR/1 (atria*		
		OR chronotro* OR period OR rate* OR control*)) OR heartbeat* OR heart-beat* OR ((respirat* OR sinus*) NEAR/1 arrhythmi*))) OR ((((cranial OR vagus OR vagal OR tenth		
		OR pneumogastric OR x) NEAR/1 (nerve* OR nervus OR tone)) OR vagatom*)) OR (((
		electrocardiogra [*] OR ekg OR ecg OR ekgs OR ecgs OR (monitoring NEAR/O holter) OR		
		vectercardiogra* OR vecter-cardiogra* OR polarcardiogra* OR polar-cardiogra*) AND variab*		
- WOS.SCI: We	eb of Sci	3))) (Topic)	298864	Fri Nov 10 2023 14:55:39 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci	4 #3 OR #2 OR #11	298864	Fri Nov 10 2023 14:56:11 GMT-0500 (Eastern Standard T
		((acute OR radia*) NEAR/1 (ache* OR hurt* OR aching OR suffer*)) OR (pain*) OR ((
		fatigu* OR lassitude)) OR (((small NEAR/0 (fibre* OR fiber*) NEAR/0 neuropath*) OR		
		erythermalgia* OR erythromelalgia*)) OR ((sciatic NEAR/O (pals* OR lesion OR neuralgia		
		OR neuralgia-neuritide [*] OR neuropath [*] OR neuritis OR neurites))) (Title) OR ((acute OR		
		radia*) NEAR/1 (ache* OR hurt* OR aching OR suffer*)) OR (pain*) OR ((fatigu* OR		
		lassitude)) OR (((small NEAR/0 (fibre* OR fiber*) NEAR/0 neuropath*) OR		
		erythermalgia* OR erythromelalgia*)) OR ((sciatic NEAR/0 (pals* OR lesion OR neuralgia		
- WOS.SCI: We	eb of Sci	OR neuralgia-neuritide* OR neuropath* OR neuritis OR neurites))) (Abstract)	1110163	Fri Nov 10 2023 14:56:56 GMT-0500 (Eastern Standard T
			1110100	
		((acute OR radia*) NEAR/1 (ache* OR hurt* OR aching OR suffer*)) OR (pain*) OR ((
		fatigu* OR lassitude)) OR (((small NEAR/0 (fibre* OR fiber*) NEAR/0 neuropath*) OR		
		erythermalgia* OR erythromelalgia*)) OR ((sciatic NEAR/O (pals* OR lesion OR neuralgia OR neuralgia-neuritide* OR neuropath* OR neuritis OR neurites))) (Topic) [®]		
- WOS.SCI: We		8	1263178	Fri Nov 10 2023 14:57:10 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci	9 #7 OR #82	1263178	Fri Nov 10 2023 14:57:37 GMT-0500 (Eastern Standard T
print doi: https://doi.u	.org/10.1101/2	023.01c3h75a2000R; this mereips porred clanuar 80.200 Rhs and in the preprint in perpetuity.		
as not centiled by p	All r	a automunder, who has granted medicate to display the preprint in perpetuity.		
		OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR		
		leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR		
		Inclose week OD headeling OD lines it into a support of the second ballows & OD headeling OD		
		melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF	R	
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma*		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma*		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR chondrosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR rleuropulmonary Blastoma* OR metastasis OR metastases OR metastatic OR carcinoid* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR		
		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR tumor*		
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR fibrosarcoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR rlubolastoma* OR pheochromocytoma* OR nephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR pheochromocytoma* OR medulloblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR tumor* OR tumour* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR		Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR chondrosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR glioblastoma* OR glioma* OR macroglobulinaemi* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR tumor* OR tumour* OR oncol*)) (Abstract)		Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR chondrosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymona* OR medulloblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR tumor* OR tumour* OR oncol*)) (Abstract)@ ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR tumor* OR tumour* OR oncol*)) (Abstract)@		Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR myelodysplastic OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR hepatocarcinoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR nephroblastoma* OR choriocarcinoma* OR rleuropulmonary Blastoma* OR metastasis OR metastases OR metastatic OR carcinoid* OR pheochromocytoma* OR nephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Abstract) ^[] ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma*		Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR ((cancer OR cancers OR cancerous OR carcinoma* OR pineoblastoma* OR tumor* OR tumour* OR oncol*)) (Abstract) ^[2] ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR cancinosarcoma* OR lymphosarcoma* OR histiocytoma* OR fibrosarcoma* OR secosarcoma* OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR		Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard Ti
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neoplas* OR malignan* OR metastasis OR "sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR mephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR mephroblastoma* OR choriocarcinoma* OR glioma* OR myelodysplastic OR metulloblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR meningioma* OR cancerous OR carcinoma* OR pineoblastoma* OR tumor* OR tumour* OR oncol*)) (Abstract) ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR tumour* OR oncol*)) (Abstract)		Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR ((cancer OR cancers OR cancerous OR carcinoma* OR pineoblastoma* OR tumor* OR tumour* OR oncol*)) (Abstract) ^[2] ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR cancinosarcoma* OR lymphosarcoma* OR histiocytoma* OR fibrosarcoma* OR secosarcoma* OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR	5120755	Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR chondrosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR medulloblastoma* OR choriocarcinoma* OR glioma* OR astrocytoma* OR myelodysplastic OR medulloblastoma* OR glioblastoma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR nacroglobulinaemi* OR pineoblastoma* OR tumor* OR tumour* OR oncol*)) (Abstract)[2] ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR thymoma* OR tumour* OR oncol*)) (Abstract)[2] ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR secosarcoma* OR chondrosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR tumour* OR oncol*)) (Abstract)[2] ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR histiocytoma* OR hepatocarcinoma* OR chondrosarcoma* OR lymphosarcoma* OR histiocytoma* OR hepatocarcinoma* OR chondrosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR tumour* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR	5120755	Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR chondrosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR medulloblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR glioma* OR astrocytoma* OR pendymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Abstract) ((cancer OR cancers OR cancerous OR carcinoma* OR hostiocytoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Abstract)	5120755	Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR chordrosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR leukemi* OR leukeami* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukeami* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neoplas* OR malignan* OR metastasis OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR tumor* OR tumour* OR oncol*)) (Abstract)] ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Abstract)] ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR tumour* OR oncol*)) (Abstract)] ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR tumour* OR hodgkin* OR "multiple myeloma" OR rethabdomyosarcoma* OR hepatocarcinoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR hepatocarcinoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR malignan* OR metas	5120755	Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR conclosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR steosarcoma* OR chondrosarcoma* OR lymphosarcoma* OR rhabdomyosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR glioma* OR astrocytoma* OR pineoblastoma* OR futumour* OR oncol*)) (Abstract)[] ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR tumor* OR tumour* OR oncol*)) (Abstract)[] ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR tumour* OR oncol*)) (Abstract)[] ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR nephatocarcinoma* OR hodgkin* OR "multiple myeloma* OR histiocytoma* OR lymphoma* OR hepatocarcinoma* OR chondrosarcoma* OR lymphosarcoma* OR histoortoma* OR hepatocarcinoma* OR hodgkin* OR "multiple myeloma* OR mesothelioma* OR neoplas* OR melanoma* OR hodgkin* OR "multiple myeloma* OR carcinoid* OR neuroblastoma* OR melanoma* OR hodgkin* OR "multiple myeloma* OR carcinoid* OR neuroblastoma* OR maligna	5120755	Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard T
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR adenocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR osteosarcoma* OR chondrosarcoma* OR sarcoma* OR neythroleukem* OR lipynphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR medulloblastoma* OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR tumor* OR tumour* OR oncol*)) (Abstract)@ ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR leukemi* OR leukemi* OR erythroleukem* OR adenocarcinoma* OR melanoma* OR concol*)) (Abstract)@ ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR nephroblastoma* OR metastasis OR metastases OR metastasis OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR nephroblastoma* OR choriocarcinoma* OR astrocytoma* OR mecohomocy	5120755	Fri Nov 10 2023 14:58:50 GMT-0500 (Eastern Standard Ti
- WOS.SCI: We		malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR fibrosarcoma* OR hepatocarcinoma* OR chondrosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR Modgkin* OR "sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR medulloblastoma* OR glioblastoma* OR carcinoja* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Abstract)@ ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Abstract)@ ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR leukemi* OR leukaemi* OR erythroleukem* OR erythroleukem* OR imphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR melanoma* OR hodgkin* OR "Neutphoma* OR erythroleukem* OR imphoma* OR melanoma* OR neoplas* OR erythroleukaem* OR erythroleukem* OR pheochromocytoma* OR hepatocarcinoma* OR carcinosarcoma* OR lymphosarcoma* OR hepatocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR setostatic OR carcinoid* OR neoplas* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR melanoma* OR hodgkin* OR metastases OR metastatic OR carcinoid* OR ne	<pre>/ 5120755 </pre>	
- WOS.SCI: We	eb of Sci 1	malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OF "Mycosis Fungoides" OR "Sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR nephroblastoma* OR choriocarcinoma* OR "Pleuropulmonary Blastoma" OR "Pleuropulmonary Blastomas" OR glioblastoma* OR glioma* OR astrocytoma* OR ependymoma* OR medulloblastoma* OR meningioma* OR craniopharyngioma* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Title) OR ((cancer OR cancers OR cancerous OR carcinoma* OR fibrosarcoma* OR hepatocarcinoma* OR chondrosarcoma* OR sarcoma* OR histiocytoma* OR fibrosarcoma* OR leukemi* OR leukaemi* OR erythroleukaem* OR erythroleukem* OR lymphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR malignan* OR metastasis OR metastases OR metastatic OR carcinoid* OR neuroblastoma* OR Modgkin* OR "sezary Syndrome" OR retinoblastoma* OR pheochromocytoma* OR medulloblastoma* OR glioblastoma* OR carcinoja* OR myelodysplastic OR myeloproliferative OR macroglobulinemi* OR macroglobulinaemi* OR pineoblastoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Abstract)@ ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR thymoma* OR tumor* OR tumour* OR oncol*)) (Abstract)@ ((cancer OR cancers OR cancerous OR carcinoma* OR histiocytoma* OR fibrosarcoma* OR leukemi* OR leukaemi* OR erythroleukem* OR erythroleukem* OR imphoma* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR melanoma* OR hodgkin* OR "Neutphoma* OR erythroleukem* OR imphoma* OR melanoma* OR neoplas* OR erythroleukaem* OR erythroleukem* OR pheochromocytoma* OR hepatocarcinoma* OR carcinosarcoma* OR lymphosarcoma* OR hepatocarcinoma* OR hepatocarcinoma* OR carcinosarcoma* OR setostatic OR carcinoid* OR neoplas* OR melanoma* OR hodgkin* OR "multiple myeloma" OR mesothelioma* OR neoplas* OR melanoma* OR hodgkin* OR metastases OR metastatic OR carcinoid* OR ne	<pre>/ 5120755 </pre>	Fri Nov 10 2023 14:58:57 GMT-0500 (Eastern Standard Ti Fri Nov 10 2023 14:58:57 GMT-0500 (Eastern Standard Ti Fri Nov 10 2023 14:59:09 GMT-0500 (Eastern Standard Ti

MIXED METHODS APPRAISAL TOOL Randomized Trials							
ITEM	S1	S2	1	2	3	4	5
Lee y, 2018	Yes	Yes	Can't tell	Yes	No	Can't tell	Yes
Burch J, 2020	Yes	Yes	Yes	Yes	No	Can't tell	No
Cheng 2019	Yes	Yes	Can't tell	Yes	Yes	Can't tell	Yes
Fernandez- Lao 2012	Yes	Yes	Yes	Yes	Can't tell	Yes	Yes
Chen S, 2019	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes

MIXED METHODS APPRAISAL TOOL Non-Randomized Trials

ITEM	S1	S2	1	2	3	4	5
Tsai H, 2021	Yes	Yes	Yes	Yes	Yes	No	Yes
Riesenberg H, 2009	Yes	Yes	Yes	Yes	Yes	Can't tell	Yes

Appendix 1. Mixed Methods Appraisal Tool Results

Chuang C, 2010	Yes	Yes	No	No	Yes	Can't tell	Yes
Aoki M, 2023	Yes	Yes	Yes	Yes	No	No	Yes
MaselL E, 2016	Yes	Yes	Yes	Yes	No	No	Yes
Lee Y, 2022	Yes	Yes	No	Yes	Can't tell	Can't tell	Yes
Uchida S, 2017	Yes	Yes	Yes	Yes	Yes	No	Yes
Fagundes C, 2011	Yes	Yes	Yes	Yes	No	Yes	Yes
Niederer D, 2013	Yes	Yes	Yes	Yes	No	Yes	Yes
Yesil H, 2018	Yes	Yes	Yes	Yes	Yes	No	Yes
Fournié C, 2021	Yes	Yes	Yes	Yes	No	No	Yes
Murofuashi K, 2023	Yes	Yes	Yes	Yes	No	Yes	Yes
Guimond A, 2018/2019	Yes	Yes	Yes	Yes	Yes	Yes	Yes

Appendix 1. Mixed Methods Appraisal Tool Results

Uchida S, 2017	Yes	Yes	Yes	Yes	Yes	No	Yes	